☰

Amol A. Padgaonkar, Ph.D.

Affiliations: 
2014 Molecular Biology and Genetics Temple University, Philadelphia, PA, United States 
Area:
Molecular Biology, Cell Biology, Oncology
Google:
"Amol Padgaonkar"
Tree Publications Grants Similar researchers PubMed Report error

Parents

Sign in to add mentor
E Premkumar Reddy grad student 2014 Temple University
 (Discovery, biological and structural characterization of ON108600, a novel kinase inhibitor in triple negative breast cancer.)

Children

Sign in to add trainee

Collaborators

Sign in to add collaborator
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Sato K, Padgaonkar AA, Baker SJ, et al. (2021) Simultaneous CK2/TNIK/DYRK1 inhibition by 108600 suppresses triple negative breast cancer stem cells and chemotherapy-resistant disease. Nature Communications. 12: 4671
Sato K, Padgaonkar A, Cosenza S, et al. (2020) Abstract P5-05-04: A novel inhibitor of cancer stem cells overcomes chemotherapy resistance of triple negative breast cancers Cancer Research
Padgaonkar A, Rechkoblit O, Vasquez-Del Carpio R, et al. (2018) Targeting protein kinase CK2 and CDK4/6 pathways with a multi-kinase inhibitor ON108110 suppresses pro-survival signaling and growth in mantle cell lymphoma and T-acute lymphoblastic leukemia. Oncotarget. 9: 37753-37765
Padgaonkar A, Cosenza S, Pallela V, et al. (2015) Abstract 4453: The dual CK2/TNIK inhibitor, ON108600 targets cancer stem cells and induces apoptosis of paclitaxel resistant triple-negative breast cancer cells Cancer Research. 75: 4453-4453
Reddy MV, Akula B, Cosenza SC, et al. (2014) Discovery of 8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a potent inhibitor of cyclin-dependent kinase 4 (CDK4) and AMPK-related kinase 5 (ARK5). Journal of Medicinal Chemistry. 57: 578-99
Roychowdhury A, Duraiswamy AJ, Maddi S, et al. (2014) Abstract 4537: Pharmacokinetics of PLK2 inhibitor GBO-006-1, developed as a novel first-in-class molecule to treat triple negative breast cancer Cancer Research. 74: 4537-4537
Godse P, Kumar P, Yewalkar N, et al. (2013) Discovery of P3971 an orally efficacious novel anticancer agent targeting HIF-1α and STAT3 pathways. Anti-Cancer Agents in Medicinal Chemistry. 13: 1460-6
Reddy MV, Mallireddigari MR, Pallela VR, et al. (2013) Design, synthesis, and biological evaluation of (E)-N-aryl-2-arylethenesulfonamide analogues as potent and orally bioavailable microtubule-targeted anticancer agents. Journal of Medicinal Chemistry. 56: 5562-86
Padgaonkar A, Rechkoblit O, Cosenza S, et al. (2013) Abstract 3239: Discovery and biological characterization of ON108600, a small molecule inhibitor of protein kinase CK2. Cancer Research. 73: 3239-3239
Manohar SM, Padgaonkar AA, Jalota-Badhwar A, et al. (2012) Cyclin-dependent kinase inhibitor, P276-00, inhibits HIF-1α and induces G2/M arrest under hypoxia in prostate cancer cells. Prostate Cancer and Prostatic Diseases. 15: 15-27
See more...